Three Bridge Wealth Advisors LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Three Bridge Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 5.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 551 shares of the medical research company’s stock after buying an additional 26 shares during the quarter. Three Bridge Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $224,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the period. Vest Financial LLC increased its stake in shares of Thermo Fisher Scientific by 73.4% during the first quarter. Vest Financial LLC now owns 3,188 shares of the medical research company’s stock worth $1,586,000 after acquiring an additional 1,349 shares during the period. Impact Capital Partners LLC increased its stake in shares of Thermo Fisher Scientific by 7.3% during the first quarter. Impact Capital Partners LLC now owns 1,024 shares of the medical research company’s stock worth $510,000 after acquiring an additional 70 shares during the period. Finally, Sivia Capital Partners LLC increased its stake in shares of Thermo Fisher Scientific by 21.6% during the first quarter. Sivia Capital Partners LLC now owns 891 shares of the medical research company’s stock worth $443,000 after acquiring an additional 158 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Barclays boosted their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research note on Thursday. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. HSBC restated a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Raymond James Financial restated an “outperform” rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $585.37.

Read Our Latest Analysis on TMO

Thermo Fisher Scientific Stock Up 3.6%

TMO stock opened at $543.88 on Monday. The company’s 50 day simple moving average is $482.58 and its 200-day simple moving average is $446.77. The firm has a market capitalization of $205.38 billion, a PE ratio of 31.46, a P/E/G ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.